Publications by authors named "Victoria Luchenko"

Claim this Profile
B
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
Julian C Bahr, Robert W Robey, Victoria Luchenko, Agnes Basseville, Arup R Chakraborty

Oncotarget· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.
Victoria L Luchenko, Thomas Litman, Arup R Chakraborty, Aaron Heffner, Christopher Devor

Mol Oncol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of a new schedule of romidepsin in patients with advanced cancers.
Laleh Amiri-Kordestani, Victoria Luchenko, Cody J Peer, Kambiz Ghafourian, James Reynolds

Clin Cancer Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
Arup R Chakraborty, Robert W Robey, Victoria L Luchenko, Zhirong Zhan, Richard L Piekarz

Blood· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Ronan J Kelly, Robert W Robey, Clara C Chen, Deborah Draper, Victoria Luchenko

Oncologist· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone deacetylase inhibitors: emerging mechanisms of resistance.
Robert W Robey, Arup R Chakraborty, Agnes Basseville, Victoria Luchenko, Julian Bahr

Mol Pharm· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
Victoria L Luchenko, Crystal D Salcido, Yongwei Zhang, Keli Agama, Edina Komlodi-Pasztor

Cell Cycle· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heat shock enhances CMV-IE promoter-driven metabotropic glutamate receptor expression and toxicity in transfected cells.
Sergey Pshenichkin, Alexander Surin, Elena Surina, Małgorzata Klauzińska, Ewa Grajkowska, Victoria Luchenko

Neuropharmacology· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
Susan E Bates, Zhirong Zhan, Kenneth Steadman, Tomasz Obrzut, Victoria Luchenko

Br J Haematol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor 1 in conditions of trophic deprivation - possible role as a dependence receptor.
Sergey Pshenichkin, Monika Dolińska, Małgorzata Klauzińska, Victoria Luchenko, Ewa Grajkowska

Neuropharmacology· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis